ME/CFS Australia (SA) Inc supports the needs of sufferers of Myalgic Encephalomyelitis, Chronic Fatigue Syndrome and related illnesses. We do this by providing services and information to members.
ME/CFS Australia (SA) Inc aims to keep members informed of various research projects, diets, medications, therapies, news items, etc. All communication, both verbal and written, is merely to disseminate information and not to make recommendations or directives.
Unless otherwise stated, the views expressed on this Web site are not necessarily the official views of the Society or its Committee and are not simply an endorsement of products or services.
Study suggests Fibromyalgia might be an immunologic disorder
Wednesday 17 April 2013
Fibromyalgia (FM) is a syndrome defined by chronic widespread pain with multiple tender points, fatigue, sleep dysfunction and abnormal pain processing. The syndrome can have many other associated symptoms as well but those can depend person to person. The cause of the syndrome is unknown but theories have revolved around the idea of a trauma or problem with the nervous system caused by injury, virus or essentially an automatic nervous system dysfunctional condition along with theories that speculate it is a sleep dysfunctional condition or it is autoimmune in nature. The role of immune system dysfunction had been downplayed in recent years due to the recent evidence to demonstrate the neurological components. If this new research into the immune system can be replicated it may very well be that Fibromyalgia is a neuroimmune syndrome in nature which could vastly change how it is looked at in research and treatment. In fact the method used in the research for their test could be used in the future diagnostically.
Looking at Cytokine cells
The researchers used several methods to study the cytokine levels of people with Fibromyalgia to healthy subjects. Cytokines are part of our immune system which are proteins that help manage our immune response. “Recent data highlight the role of the immune system in FM. Aberrant expressions of immune mediators, such as cytokines, have been linked to the pathogenesis and traits of FM. We therefore determined whether cytokine production by immune cells is altered in FM patients by comparing the cellular responses to mitogenic activators of stimulated blood mononuclear cells of a large number of patients with FM to those of healthy matched individuals.” Prohealth
The study was done by the blind method. There were a total of 110 Fibromyalgia subjects and 91 control subjects involved. All the FM subjects had symptoms and a diagnosis of at least one year and underwent two independent examinations to confirm they met criteria according to the standards of the American College of Rheumatology. All FM patients were off their fibromyalgia medications two weeks prior to the study being started. Patients with comorbid conditions were excluded specifically ones with already compromised immune systems; such as autoimmune conditions. Median age of the group was 39.
The study done by BMC Clinical Pathology (December 17, 2012) “Plasma and peripheral blood mononuclear cells (PBMC).... Parallel samples of PBMC were cultured overnight in medium alone or in the presence of mitogenic activators; PHA or PMA in combination with ionomycin. The cytokine concentrations of IFN-γ, IL-5, IL-6, IL-8, IL-10, MIP-1β , MCP-1, and MIP1-α in plasma as well as in cultured supernatants were determined using a multiplex immunoassay using bead array technology.
Essentially Fibromyalgia patients had substantially lower levels that the control group. Cytokine levels “of stimulated PBMC cultures of healthy control subjects were significantly increased as compared to matched non-stimulated PBMC cultures. In contrast, the concentrations of most cytokines were lower in stimulated samples from patients with FM compared to controls. The decreases of cytokine concentrations in patients samples ranged from 1.5-fold for MIP-1β to 10.2-fold for IL-6 in PHA challenges. In PMA challenges, we observed 1.8 to 4-fold decreases in the concentrations of cytokines in patient samples.” BMC Clinical Pathology December 17, 2012
The research done by BMC Clinical Pathology (December 17, 2012) concludes “The cytokine responses to mitogenic activators of PBMC isolated from patients with FM were significantly lower than those of healthy individuals, implying that cell-mediated immunity is impaired in FM patients. This novel cytokine assay reveals unique and valuable immunologic traits, which, when combined with clinical patterns, can offer a diagnostic methodology in FM.”
“In the past, FM was claimed to be a rheumatologic, neurologic or psychiatric disease despite the fact that there were no objective links to any of those pathways. Our findings uncovered evidence that FM is instead an immunologic disorder. They prove that the immunologic basis of FM occurs independently of any subjective features. Hence, this illustrates the very strong clinical value of our test protocol. The fact that individual cytokines exhibited similar dynamics in patient samples reveals that the FM patients are uniform in regard to their cellular immunologic responses.” BMC Clinical Pathology December 17, 2012
Based on one study there is not enough evidence to say that Fibromyalgia is an immunologic disorder, but if more studies confirm similar findings accross patients with FM it could mean a great deal. There has been a shift to see the syndrome as neurological and this would increase the shift towards neuroimmune. This means a great deal since it is pointing to specific immune dysfunction which could lead to a better overall grasp of what is going on with this syndrome. Most important is the idea that they could come up with a diagnostic tool, which the lack of has always been a problem. It could lead to people being diagnosed early and prevent misdiagnosis if there was a diagnostic tool.
Suggested by the author:
The above originally appeared here.
blog comments powered by Disqus